{
  "docId": "019de077-58c2-77ec-8b05-6d27c4bb0498",
  "docSlug": "35a6e53e15f172ec3a7e4b1f473eaa42",
  "documentTitle": "Genprex | Investor Presentation Deck | 58 slides",
  "authorId": "genprex",
  "authorName": "Genprex",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 58,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a 'problem-solution' framing, highlighting the limitation of existing drugs and the mechanism of the company's therapy.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de077-58c2-77ec-8b05-6d27c4bb0498/18",
  "deckHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498",
  "deckJsonHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498.json",
  "deckAnchorHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.9,
        "w": 0.4,
        "x": 0.55,
        "y": 0.05
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6e58f5e-f210-4671-924e-155b4f7adc36",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "REQORSA Immunogene Therapy may be complementary with targeted drugs and immunotherapies. REQORSA’s multimodal activity may block emerging bypass pathways, thereby potentially reducing the probability that drug resistance develops.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee692dc9-7dbb-4cd6-abae-452693ccc85c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Our approach is designed to address drug resistance.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8510b8fa-5d33-48e6-97e3-5a0bd9a0835f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "For most patients, drug resistance to Tagrisso and Tecentriq is inevitable.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad378484-634d-4182-a7e9-ad13f771eb34",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "6b26bebf-31db-4d60-8714-661219b5ed1e",
      "evidence": "title/action-title: For most patients, drug resistance to Tagrisso and Tecentriq is inevitable.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "2a8dee85-f59a-4bef-8d80-e68976c69a7f",
      "evidence": "Identifies the problem (inevitable drug resistance) and bridges to the solution (REQORSA therapy).",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "42876aa5-a597-4386-a7a4-77eba640e28a",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Solution overview and clinical trial results",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 18,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6f78c908-9d3e-4d22-b345-671df04f3614",
      "evidence": "Discussion of drug resistance and limited treatment options",
      "position": 0,
      "objective": "Highlight the consequences of not adopting Genprex's gene therapies",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}